09-Dec-2017
On Wednesday December 6th, Professor Angelyn Bethel presented new data from the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). The invited talk, presented within the "Latest Cardiovascular Clinical Trials" symposium, shared a new meta-analysis of the four glucagon-like peptide-1 receptor agonist cardiovascular outcome trials conducted to date. This analysis, which was published simultaneously in The Lancet Diabetes and Endocrinology, showed an overall favourable risk-benefit balance for the class on important cardiovascular and safety outcomes. A slide deck summarising the presentation can be downloaded here.